Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (16).
- Dividend Declaration
The Board of Directors has recommended 60% Cash Dividend for the year ended June 30, 2026. The convening of the 50th Annual General Meeting (AGM) of the Company, relating to the financial year 2025-26, is dependent upon the holding of the 49th AGM, relating to the financial year 2024-25. An application seeking condonation of the delay in holding the 49th AGM (Company Matter No. 1112 of 2026) is pending before the Hon'ble High Court Division (cont.1) (Cont. News of BXPHARMA): Record Date: 19.11.2026. The Company has also reported Consolidated EPS of Tk. 20.17, Consolidated NAV per share of Tk. 139.18 and Consolidated NOCFPS of Tk. 21.33 for the year ended June 30, 2026 as against Tk. 15.56, Tk. 119.04 and Tk. 16.19 respectively for the year ended June 30, 2025. (end) (Cont. News of BXPHARMA): of the Supreme Court of Bangladesh. The hearing has been concluded, and the Court's judgment is scheduled to be delivered on 1 November 2026. Accordingly, the date, time and other arrangements for the 49th and 50th AGMs will be communicated to the shareholders in due course, following the Court's judgement and in accordance with applicable legal and regulatory requirements. (cont.2)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2026) following its corporate declaration.
- Change of Board Meeting Time under LR 19(1)
The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 28, 2026 at 4:00 PM instead of 5:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2026 at 5:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.
- Resumption after Record Date
Trading of the shares of the company will resume on 03-Aug-2026.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 02-Aug-2026.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 29.07.2026 to 30.07.2026 and trading of the shares will remain suspended on record date i.e., 02.08.2026.
- Credit Rating Result
Credit Rating Information and Services PLC (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" for short term along with Stable outlook in consideration of its audited financials up to June 30, 2025 also unaudited financials up to March 31, 2026 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Dividend Declaration
The Board of Directors has recommended 47.5% Cash Dividend for the year ended June 30, 2025. Date & Time of AGM: The Annual General Meeting (AGM) will be convened at the earliest practicable time, subject to obtaining the necessary permission and condonation of delay from the Hon'ble High Court Division of the Supreme Court of Bangladesh. Record Date: 02.08.2026. (cont.) (Cont. News of BXPHARMA): The Company has also reported Consolidated EPS of Tk. 15.56, Consolidated NAV per share of Tk. 119.04, and Consolidated NOCFPS of Tk. 16.19 for the year ended June 30, 2025, as against Tk. 13.07, Tk. 107.48, and Tk. 18.75 respectively for the year ended June 30, 2024. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (24.06.2026) following its corporate declaration.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 5.30 for July-September 2025 as against Tk. 3.77 for July-September 2024. Consolidated NOCFPS was Tk. 6.14 for July-September 2025 as against Tk. 3.80 for July-September 2024. Consolidated NAV per share was Tk. 124.34 as on September 30, 2025 and Tk. 111.25 as on September 30, 2024. Reasons for significant deviations: The notable growth in net revenue during the reporting quarter compared to the corresponding prior period, (cont.1) (Cont. News of BXPHARMA): These factors, together with reduced cash outflows related to working capital, contributed to a favorable deviation in Net Operating Cash Flows Per Share during the reporting period. (end) (Cont. News of BXPHARMA): along with the resulting leverage effect on gross margin, lower finance costs driven by improved cash inflows, and higher other income mainly on account of royalty and cash incentives earned against exports, collectively contributed to the significant increase in EPS. Additionally, improved financial performance of the subsidiary companies Synovia and Nuvista Pharma also positively contributed to the consolidated growth in EPS. (cont.2)
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 5.28 for October-December 2025 as against Tk. 4.10 for October-December 2024; Consolidated EPS was Tk. 10.58 for July-December 2025 as against Tk. 7.87 for July-December 2024. Consolidated NOCFPS was Tk. 11.16 for July-December 2025 as against Tk. 6.13 for July-December 2024. Consolidated NAV per share was Tk. 129.63 as on December 31, 2025 and Tk. 111.35 as on December 31,2024. Reasons for deviations: (cont.1) (Cont. news of BXPHARMA): These factors, together with reduced cash outflows related to working capital, contributed to the favorable deviation in NOCFPS. (end) (Cont. news of BXPHARMA): The notable growth in net revenue compared to the corresponding prior period, along with the resulting leverage effect on gross margin, lower finance costs driven by improved cash inflows, and higher other income mainly on account of royalty and cash incentives earned against exports, collectively contributed to the significant increase in EPS during half year period. (cont.2)
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 4.98 for January-March 2026 as against Tk. 3.86 for January-March 2025; Consolidated EPS was Tk. 15.56 for July 2025-March 2026 as against Tk. 11.73 for July 2024-March 2025. Consolidated NOCFPS was Tk. 16.74 for July 2025-March 2026 as against Tk. 9.46 for July 2024-March 2025. Consolidated NAV per share was Tk. 134.60 as on March 31, 2026 and Tk. 115.21 as on March 31, 2025. (Q3 Un-audited): Consolidated EPS was Tk. 3.86 for January-March 2025 as against Tk. 3.06 for January-March 2024; Consolidated EPS was Tk. 11.73 for July 2024-March 2025 as against Tk. 9.75 for July 2023-March 2024. Consolidated NOCFPS was Tk. 9.46 for July 2024-March 2025 as against Tk. 14.79 for July 2023-March 2024. Consolidated NAV per share was Tk. 115.21 as on March 31, 2025 and Tk. 104.17 as on March 31, 2024.
- Board Meeting schedule under LR 19(1)
The Company has informed that pursuant to the consent obtained from Bangladesh Securities and Exchange Commission vide their letter No. SEC/SRMIC/94-34/Part-X/124 dated June 21, 2026, a meeting of the Board of Directors will be held on June 23, 2026 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Board Meeting schedule under LR 16(1)
The Company has informed that pursuant to the consent obtained from Bangladesh Securities and Exchange Commission vide their letter No. SEC/SRMIC/94-34/Part-X/124 dated June 21, 2026, a meeting of the Board of Directors will be held on June 23, 2026 at 3:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2025. (cont.) (Cont. News of BXPHARMA): First Quarter (Q1) period ended September 30, 2025, Second Quarter (Q2) period ended December 31, 2025 and Third Quarter (Q3) period ended March 31, 2026. (end)
- Clarification on recent news published in website/online news portal
In response to a DSE query letter to the company regarding a news published in the website/online news portal titled "Trading of Beximco Pharma is being suspended on the London Stock Exchange" (translated from Bengali to English) on December 26, 2025, the company has informed DSE, among others, the following: "?1. Pursuant to Rule 19 of the AIM Rules for Companies, an AIM-listed issuer is required to publish its Annual Report and Accounts within six months of the end of its financial year. (cont.1) (Cont. News of BXPHARMA): The said announcement is publicly available on the Company's website (www.beximcopharma.com). 2. The temporary suspension relates solely to trading of the Company's GDRs on AIM and there is no known financial implication on the Company for this temporary suspension." (end) (Cont. News of BXPHARMA): Where publication is not completed within this period, the AIM regulations provide for a precautionary suspension of trading of the relevant AIM securities. In compliance to the AIM regulations, the Company made an announcement on AIM of London Stock Exchange on 19 December 2025, informing the market of the temporary suspension of trading of its GDRs with effect from 7:30 a.m. on 2 January 2026. (cont.2)
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.